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Abstract. – OBJECTIVE: Cumulative expo-
sure of the skin to ultraviolet radiation promotes
mutation in keratinocytes and their abnormal
growth led to the formation of scaly lesions,
called actinic keratoses (AKs). Its incidence is
growing at an emerging rate, becoming a world-
wide problem especially for occupational ultravi-
olet (UV) rays exposure. Detectable lesions are
often associated with field changes, where the
surrounding skin is altered and subclinical le-
sions may be present. Thus, a field-directed ther-
apy, such as topical treatment, should be pre-
ferred for the prevention of invasive cancer de-
velopment. A retrospective analysis was made,
evaluating the efficacy of ingenol-mebutate gel,
using a novel device the 3D in vivo optical skin
Imaging (Antera 3D, Miravex, Ireland).
PATIENTS AND METHODS: We included all
patients with multiple non-hypertrophic Aks, to
whom it was prescribed ingenol-mebutate gel,
applied at the dosages of 0.015 for lesions in
the scalp/face (for 3 consecutive days) and at
the dosage of 0.05% for lesions in the trunk
and/or extremities (for 2 consecutive days).
RESULTS: A reduction of the lesions and of
median hemoglobin levels, after a follow-up of
60 days, was observed in 100% of patients.
CONCLUSIONS: Ingenol mebutate gel, the
last topical molecule appeared in the Italian
market showed its efficacy using Antera 3D al-
so in terms of hemoglobin reduction. Therefore,
this camera could be considered an useful tool
for the identification of the area to be treated
and for therapeutic follow-up.
Key Words:
Actinic keratosis, Antera 3D, Cancerization field, Eu-
phorbia pheplus, Sun damage.
Introduction
Actinic Keratosis (AKs) are keratotic lesions
occurring on chronically light-exposed adult
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skin, especially in fair-skinned people. They rep-
resent the earliest manifestation of squamous cell
carcinoma (SCC), often considered in situ skin
cancer, since they share histological and molecu-
lar aspects1. Normal-appearing skin, surrounding
AKs, frequently expresses molecular changes in
the form of p53 mutations. The whole area,
therefore, has the potential to develop AK, a
chronic condition in which new or recurrent le-
sions continue to develop over time, on a back-
ground of subclinical disease1,2. Ultraviolet (UV)
radiations, considered completed carcinogens,
leads to multiple genetic (and epigenetic) alter-
ations, that promote preferential growth of al-
tered keratinocytes, which may ultimately mani-
fest as malignant evolution3. In young age, the
body can repair some of the damage, over the
time the damage accumulates and the body is
less able to repair itself. The process commonly
starts on large fields of skin exposed to UV radi-
ation (“field cancerization”) and if UV rays con-
tinue to hit the skin, AK or other skin cancers
arise. It was observed that a patient with multiple
Aks (>5) has an annual risk of developing inva-
sive squamous cell carcinoma ranging up to
80%; 82.4% of SCC derived from previous AK
and/or in close proximity, but none is able to pre-
dict which of them will progress3-5. They affect
half of the global population and prevalence may
vary with geographical location and age. The di-
agnosis of AK is typically made clinically, de-
tectable only as an area of roughening on the
skin surface. Patients often refer a history of re-
lapsing, remitting lesions, therefore if left un-
treated they may turn into more invasive skin
cancer. The new therapeutic approach is oriented
to make an early diagnosis and to treat all lesions
as earlier as possible. Many treatment modalities
are available, although recent developments have
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focused on the management of the whole actini-
cally damaged field6. Recently approved in the
italian market, ingenol mebutate, in two formula-
tions (0.05% trunk and extremities 0.015% face
and scalp), for the treatment of multiple non-hy-
pertrophic AKs, has giving interesting results7.
We evaluated its efficacy with Antera 3D (Mi-
ravex, Limited, Dublin, Ireland)8.
Patients and Methods
A retrospective data analysis was performed
in the AKs unit of our dermatological depart-
ment. All patients signed consent forms and
were informed about the treatments procedures
and local skin reactions (LRS). We included in
the analysis all patients with multiple non-hy-
pertrophic actinic keratosis to whom it was pre-
scribed ingenol-mebutate gel, 0.015% for le-
sions in the scalp (for 3 consecutive days) and
0.05% for lesions in the trunk and/or extremi-
ties (for 2 consecutive days). The aim of the
current report was not to evaluate the clinic-
pathological predictors for a better response to
treatment, while its efficacy using a novel de-
vice the in vivo optical skin imaging (Antera
3D, Miravex, Limited, Dublin, Ireland) which
Figure 1. Clinical pictures of 3 different patients at baseline, during LRS and after treatment with ingenol mebutate 0.015%,
for 3 consecutive days. Patient n. 1 A, A Caucasian female showing multiple non hypertrophic actinic keratosis on the nose
and left cheek at baseline. B, Same patient after 4 days of application of ingenol mebutate gel 0.015 showing low-grade
inflammation, just slight erythema and oedema without blistering, erosion and crusts. C, Same patient, after 60 days of
treatment showed a complete resolution with great cosmetic results, healthy skin and complete AKs clearance. Patient n. 2 A,
Caucasian female, with multiple non hypertrophic actinic keratosis on her forehead at baseline. B, Same patient after 4 days of
ingenol mebutate 0.015% application, we observed a mild local skin reaction with oedema, erythema, erosion and crusts. C,
Same patient, with a complete resolutions of LRS and healthy skin, without scars and complete AKs clearance after 60 days.
Patient n. 3 A, A Caucasian male with multiple non hypertrophic actinic keratosis on the left check at baseline B, Same
patient, after 4 days of ingenol mebutate 0.015% application showing a severe local skin reaction, with severe erythema,
oedema, blistering, sterile pustules also outside application area and erosions. C, Same patient, after 60 days of application, a
complete resolution with evident healthy skin, with no scars and a complete AKs cleareance.
allows the view of skin in 2 or 3 dimensions as
well as multi-spectral analysis. Patients were
collected according to sex, age (≤ 60 or ≥61
years), reduction in number of cutaneous le-
sions, satisfaction (reduction of AK and an aes-
thetic performance), vascularization and in-
flammation severity. The image acquisition was
performed at baseline, during LRS and after the
treatment and retrospectively evaluated, ac-
cording to treated lesion’s vascularization
severity and relative inflammation. This para-
meter was evaluated considering the concentra-
tion of hemoglobin (directly proportional to the
grade of vascularization) with Antera 3D.
Statistical Analysis
Assuming that the effects of the variables are
constant over time, an Odds Ratio (OR) was per-
formed to evaluate the number of clinical re-
sponses and morphological evaluations at the
imaging device. A p value < 0.05 was considered
statistically significant.
Results
A total of 65 patients treated with ingenol-
mebutate gel for AKs were enrolled in current
report. Thirty-five case series of patients were
male (54%) and 58 were ≥ 61 years old (89%).
A reduction of the lesions (as a reduction in the
number of lesions ≥ 51% of the total number of
lesions), after a follow-up of 60 days, was ob-
served in 100% of patients. At the same time the
patient’s satisfaction increased directly with the
disappearance of Aks (97% after 60 days) (Fig-
ure 1). Starting from these results we decided to
evaluate AK’s vascularization before and after
treatment, as well as the inflammation degree. A
measurement of hemoglobin was used to identi-
fy tiny blood vessels and follows the treatment
efficacy. A reduction of median hemoglobin lev-
els was observed in all patients analyzed. Per-
forming Odds-Ratio, a statistical significance
was reached, showing a p < 0.001 (OR: 201). At
the same time we observed an inflammation re-
duction after the treatment, showing an OR of
0.4 with a p value < 0.05 (Figures 2, 3). In con-
clusion, vascularization of the treated areas
showed a reduction after a follow-up of 60 days,
with a relative clinical reduction of inflamma-
tion, associated also with an aesthetic perfor-
mance, as reported by the high value of pa-
tient’s satisfaction.
Discussion
AKs are considered a worldwide problem
with continuously increasing incidence, con-
sidered as an early step in the continuum of
transformation from normal skin to invasive
SCC9. The new treatment approach is focused
on possible recurrence of existing lesions ver-
sus emergence of new AK lesions in a similar
area (actinic field). In this regards, ingenol
mebutate gel, applied as field therapy, was re-
tretrospectively considered for the treatment of
multiple non-hypertrophic AKs. The results of
our analysis showed that ingenol mebutate gel
was effective when treating head or body ac-
tinic keratoses, producing clinically relevant
clearance and reduction in the number of le-
sions in the selected field due to its dual mech-
anism of action, that combines rapid direct cell
death with a neutrophil-mediated immune re-
sponse10. According to literature, LRs were ex-
perienced in the majority of our treated pa-
tients, although they resolved after 15 days,
without scars or skin colour change (often
seen with criosurgery), without evidence of
skin sensitization, photoirritation, or photoal-
lergy, they did not need any additional treat-
ment and did not influence patient’s adherence
to treatment, since we explained what could
happen during the first visit11. As observed in
clinical pictures, a complete resolution was
achieved with an improvement in skin quality
(after 60 days), in fact patients were satisfied
about clinical efficacy and aesthetic outcome,
they had the feeling of visible healthy skin. We
also evaluated its efficacy using in vivo optical
skin imaging, which showed tridimensional
appearance of the skin, vascular pattern,
melanogenic distribution and wrinkles, focus-
ing our interest on the vascular aspect12. As
known, metastatic spread, of cancer cells de-
pends on an adequate supply of oxygen and
nutrients and the removal of waste products. In
this regard, tumor growth and metastasis de-
pend on neo-angiogenesis and lymphangiogen-
esis, triggered by chemical signals from tumor
cells in a phase of rapid growth13. Pathological
angiogenesis occurs in skin cancers and is a
crucial pathway in tumor biology in general.
In fact, certain stimuli promote a pro-angio-
genic microenviroment such as acute ultravio-
let damage, which causes dramatic changes in
growth factor cytokines in normal skin14.
Transformed lesions are capable of growth up
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to 2 mm in diameter before their metabolic de-
mand exceed the available blood supply lead-
ing the switch to the angiogenic phenotype. In
fact, compared to physiological skin, AKs
show an increment of vascularization (patho-
logical neo-angiogenesis) and exhibit capillary
densities greater than surrounding normal tis-
sue, which becomes more severe and evident
in invasive tumoral lesions. As showed in the
current study, the use of ingenol-mebutate gel
has reduced the median levels of hemoglobin
(directly related to the vascularization) showed
by Antera (p < 0.001), supposing a possible re-
duction of the risk of tumoral progression.
Contrasting this process will be useful in the
prevention and early intervention in skin can-
cers. In this view, our study, focused on vascu-
lar pattern, demonstrated the reduction of he-
moglobin content in Aks, after ingenol appli-
cation, allowing a better therapeutical ap-
proach to every single lesion. A reduction of
median hemoglobin levels was observed after
60 days, showing a reduction of AK’s vascu-
larization. However, further studies are needed
to corroborate this hypothesis. This simple
camera could be considered an useful tool in
the everyday dermatological practice to evalu-
ate treatment follow-up.
Figure 2. Images of the same patient have been acquired with Antera® (Miravex). A, Clinical tridimensional image acquired
with Antera® (Miravex) showing multiple actinic keratosis over the zygomatic and nasal region at baseline. B, The
hemoglobin analysis using Antera® (Miravex), showed a pseudo-crateriform shape of the actinic keratosis with an high
vascular component at baseline. After 4 days of application of Ingenol mebutate gel 0.015% a mild inflammation was observed
in the treated area, as showed by figures C (tridimensional) and D (hemoglobin distribution). E, Tridimensional image showed
a complete lesions resolution after a follow up of 60 days, F, An important decrease of mean hemoglobin values (directly
related to a reduction of vascularization) was observed.
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Conclusions
Ingenol mebutate can be considered an effec-
tive, innovative and cost effective treatment ac-
cepted by patients especially for its short dura-
tion (just two or three consecutive days of appli-
cation), which is changing italian style to treat
AKs in the near future15. Ingenol mebutate, can
be used the whole year around as first line treat-
ment.
–––––––––––––––––––
Acknowledgements
Our special thanks to Dr Vincent Li, The Angiogenesis
Foundation, Cambridge, MA, Angiogenesis Center, Derma-
tology Department, Brigham & Women’s Hospital and Har-
vard Medical School, Boston, MA, for his always precious
teachings we thank our patients for their cooperation. The
authors would also like to acknowledge colleagues who
have contributed in different aspects and Valerio Barletta
and Valerio Filacchioni for their help.
–––––––––––––––––-–––
Conflict of Interest
The Authors declare that they have no conflict of interests.
References
1) RIGEL DS, STEIN GOLD LF. The importance of early
diagnosis and treatment of actinic keratosis. J Am
Acad Dermatol 2013; 68(1 Suppl 1): S20-27.
2) TRAIANOU A, ULRICH M, APALLA Z, DE VRIES E, BAKIRTZI
K, KALABALIKIS D, FERRANDIZ L, RUIZ-DE-CASAS A,
MORENO-RAMIREZ D, SOTIRIADIS D, IOANNIDES D,
Figure 3. Images of the same patient have been acquired with Antera® (Miravex). A, Clinical tridimensional image showed
multiple non hypertrofic actinic keratosis in a photodamaged skin at baseline (A tridimensional view-B hemoglobin
distribution). B, Showed multiple “red spots”, corresponding to high levels of hemoglobin and high vascularization at baseline.
C, 60 days after treatment, disappearance of actinic keratosis was observed in tridimensional image and D. As showed also by
the reduction of intensity of the “red spots” (hemoglobin and vascular components). A reduction of the lesions (as a reduction
in the number of lesions ≥ 51% of the total number of lesions), after a follow-up of 60 days, was observed in 100% of patients
in follow-up.
97
Evaluation of Ingenol mebutate efficacy for the treatment of actinic keratosis with Antera 3D camera
AQUILINA S, APAP C, MICALLEF R, SCERRI L, PITKÄNEN S,
SAKSELA O, ALTSITSIADIS E, HINRICHS B, MAGNONI C,
FIORENTINI C, MAJEWSKI S, RANKI A, PROBY CM, STOCK-
FLETH E, TRAKATELLI M; EPIDERM Group. Risk fac-
tors for actinic keratosis in eight European cen-
tres:a case-control study. Br J Dermatol 2012;
167(Suppl 2): 36-42.
3) RATUSHNY W, GOBER MD, HICK R, RIDKY TW, SEYKORA
JT. From keratinocyte to cancer: the pathogenesis
and modeling of cutaneous squamous cell carci-
noma. J Clin Invest 2012; 122: 464-472.
4) MITTELBRONN MA, MULLINS DL, RAMOS-CAR FA, FLOW-
ERS FP. Frequency of pre-existing actinic keratosis
in cutaneous squamous cell carcinoma. Int J Der-
matol 1998; 37: 677-681.
5) STOCKFLETH E, FERRANDIZ C, GROB JJ, LEIGH I, PEHAM-
BERGER H, KERL H; European Skin Academy. Devel-
opment of a treatment algorithm for actinic ker-
atoses: a European Consensus. Eur J Dermatol
2008; 18: 651-659.
6) CANTISANI C, DE GADO F, ULRICH M, BOTTONI U, IACO-
BELLIS F, RICHETTA AG, CALVIERI S. Actinic keratosis: re-
view of the literature and new patents. Recent Pat
Inflamm Allergy Drug Discov 2013; 7: 168-175.
7) LEBWOHL M, SHUMACK S, STEIN GOLD L, MELGAARD A,
LARSSON T, TYRING SK. Long-term follow-up study of
ingenol mebutate gel for the treatment of actinic
keratoses. JAMA Dermatol 2013; 149: 666-670.
8) COMA M, VALLS R, MAS JM, PUJOL A, HERRANZ MA,
ALONSO V, NAVAL J. NAVAL. Methods for diagnosing
perceived age on the basis of an ensemble of
phenotypic features. Clin Cosmet Investig Derma-
tol 2014; 7: 133-137.
9) DELTONDO JA, HELM KF. Actinic keratosis: precan-
cer, squamous cell carcinoma, or marker of field
cancerization? G Ital Dermatol Venereol 2009;
144: 441-444.
10) ROSEN R, GUPTA AK, TYRING SK. Dual mechanism of
action of ingenol mebutate gel for topical treat-
ment of actinic keratoses: rapid lesion necrosis
followed by lesion-specific immune response. J
Am Acad Dermatol 2012; 66: 486-493.
11) LONGO C, NERI L, ARGENZIANO G, CALVIERI S,
CALZAVARA-PINTON PG, CANTISANI C, CATRICALÀ C,
PERIS K, PESERICO A, PIMPINELLI N, PELLACANI G. Man-
agement of local skin reactions after the applica-
tion of ingenol mebutate gel for the treatment of
actinic keratosis: four illustrative cases. J Eur
Acad Dermatol Venereol 2014 Sep 3. [Epub
ahead of print].
12) KOHL E, MEIERHÖFER J, KOLLER M, ZEMAN F, KLEIN A,
HOHENLEUTNER U, LANDTHALER M, HOHENLEUTNER S.
Fractional carbon dioxide laser resurfacing of
rhytides and photoageing: a prospective study us-
ing profilometric analysis. Br J Dermatol 2014;
170: 858-865.
13) LI VW, LI WW. Angiogenesis in the treatment of
skin cancer. J Drugs Dermatol 2008; 71(1 Suppl
1): s17-24.
14) ALBINI A, TOSETTI F, LI VW, NOONAN DM, LI WW.
Cancer prevention by targeting angiogenesis. Nat
Rev Clin Oncol 2012; 9: 498-509.
15) DRENO B, AMICI JM, BASSET-SEGUIN N, CRIBIER B,
CLAUDEL JP, RICHARD MA. Management of actinic
keratosis: a practical report and treatment algo-
rithm from AK-Team™ expert clinicians. J Eur
Acad Dermatol Venereol 2014; 28: 1141-1149
